379 related articles for article (PubMed ID: 19696006)
1. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study.
Kellokumpu-Lehtinen P; Bergh J; Salminen E; Wiklund T; Lehtinen S; Aronen P; Sintonen H
Acta Oncol; 2007; 46(2):146-52. PubMed ID: 17453362
[TBL] [Abstract][Full Text] [Related]
3. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Poncet B; Bachelot T; Colin C; Ganne C; Jaisson-Hot I; Orfeuvre H; Peaud PY; Jacquin JP; Salles B; Tigaud JD; Mechin-Cretinon I; Marechal F; Fournel C; Trillet-Lenoir V
Am J Clin Oncol; 2008 Aug; 31(4):363-8. PubMed ID: 18845995
[TBL] [Abstract][Full Text] [Related]
4. Health care costs for treatment of disseminated breast cancer.
Dahlberg L; Lundkvist J; Lindman H
Eur J Cancer; 2009 Jul; 45(11):1987-91. PubMed ID: 19398326
[TBL] [Abstract][Full Text] [Related]
5. [Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer].
Martin JP; Diéras V; Berdeaux G
Therapie; 2000; 55(1):127-31. PubMed ID: 10860013
[TBL] [Abstract][Full Text] [Related]
6. Economic and cost-effectiveness issues in breast cancer treatment.
Hillner BE
Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
[TBL] [Abstract][Full Text] [Related]
7. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Nerich V; Chelly J; Montcuquet P; Chaigneau L; Villanueva C; Fiteni F; Meneveau N; Perrin S; Voidey A; Monnot T; Pivot X; Limat S
J Oncol Pharm Pract; 2014 Oct; 20(5):362-8. PubMed ID: 24158979
[TBL] [Abstract][Full Text] [Related]
8. Survival impact of integrative cancer care in advanced metastatic breast cancer.
Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
[TBL] [Abstract][Full Text] [Related]
9. Metastatic breast cancer: we do need primary cost data.
Bonastre J; Jan P; Barthe Y; Koscielny S
Breast; 2012 Jun; 21(3):384-8. PubMed ID: 22520336
[TBL] [Abstract][Full Text] [Related]
10. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
Stäbler W; Wagner B
Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
[TBL] [Abstract][Full Text] [Related]
11. [Treatment patterns in advanced breast cancer with anthracycline and taxanes and their costs in three public hospitals of Mexico].
Silva JA; Gonzalez JF; Bargalló JE; Hernández-Rivera G; Gómez-Roel X; Rangel S; Vargas-Valencia JJ; Martínez-Fonseca J; Donato BM; Juárez-García A
Value Health; 2011; 14(5 Suppl 1):S147-50. PubMed ID: 21839890
[TBL] [Abstract][Full Text] [Related]
12. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer.
De Rosa L; Lalle M; Pandolfi A; Pescador L
Bone Marrow Transplant; 2001 May; 27(10):1031-5. PubMed ID: 11438817
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.
Marino P; Roché H; Moatti JP;
Am J Clin Oncol; 2008 Apr; 31(2):117-24. PubMed ID: 18391594
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
Görner M; Riemer-Hommel P
Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
[TBL] [Abstract][Full Text] [Related]
15. How to make the best use of limited resources in breast cancer treatment--experiences in Bosnia & Herzegovina.
Obralić N; Beslija S
J BUON; 2006; 11(1):21-9. PubMed ID: 17318948
[TBL] [Abstract][Full Text] [Related]
16. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer.
Dufresne A; Pivot X; Tournigand C; Facchini T; Altweegg T; Chaigneau L; De Gramont A
Breast Cancer Res Treat; 2008 Jan; 107(2):275-9. PubMed ID: 17380382
[TBL] [Abstract][Full Text] [Related]
17. Patterns of chemotherapy usage in hospitalized breast cancer patients.
Sookprasert A; Chindaprasirt J; Wirasorn K; Limpawattana P; Thavornpitak Y
J Med Assoc Thai; 2012 Jul; 95 Suppl 7():S206-10. PubMed ID: 23130456
[TBL] [Abstract][Full Text] [Related]
18. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
Hassett MJ; O'Malley AJ; Pakes JR; Newhouse JP; Earle CC
J Natl Cancer Inst; 2006 Aug; 98(16):1108-17. PubMed ID: 16912263
[TBL] [Abstract][Full Text] [Related]
19. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
20. Aggressiveness of cancer-care near the end-of-life in Korea.
Keam B; Oh DY; Lee SH; Kim DW; Kim MR; Im SA; Kim TY; Bang YJ; Heo DS
Jpn J Clin Oncol; 2008 May; 38(5):381-6. PubMed ID: 18411260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
